Q2 2025 | NEWSLETTER
Onego Bio Q2: Manufacturing Milestones, USDA Progress & Series B Ahead
As we advance into the second half of the year, we are meeting planned milestones including: progressing our scale-up capabilities, nearing final regulatory review and approval in the US market, supplying Bioalbumen® to partners and customers and actively collaborating with them in trials and recipe application.
While we prepare for our next chapter, we’re also planning an important step forward: we are looking ahead to our Series B fundraise, and have already secured some initial commitments. If you’re interested in engaging and helping us strengthen the global egg supply chain, this is the right time to connect.
Warm regards,
Founders, Onego Bio
1. USDA Progress: Jefferson County Facility Advances
Onego Bio has been selected to proceed into Phase 2 of the application process for funding consideration under the Biorefinery, Renewable Chemical, and Biobased Product Manufacturing Assistance Program (9003 Program). This program allows for up to a $250 million loan commitment from the U.S. Department of Agriculture to support the development of our Jefferson County production facility.
This is an important step in our roadmap to build our own manufacturing capabilities. It’s also a powerful signal from our first target market. As we bring Bioalbumen® to the U.S., this affirms the strength of our business case and the strategic relevance of our technology platform in addressing national food security, supply resilience, and sustainable ingredient sourcing.
Both the USDA’s (and DoD’s) support to date and advancement of our application in this process underscores the importance of egg supply and the readiness of U.S. stakeholders to invest in forward-looking food infrastructure— positioning Onego Bio at the forefront of that movement.
2. Scale Up Measures
TECHNICAL MILESTONES AND FIRST TON PRODUCED:
In Q2, we achieved several key technical milestones (please reach out for more technical information):
Made progress to improve commercial unit economics and further de-risk scale-up
Completed our first 1,000 kilos (1 ton) of Bioalbumen® production with our co-manufacturing partner
After almost two years of preparation, we filed a strategic, high-value patent with both the United States Patent and Trademarks Office and the European Patent Office
MACROECONOMICS AND IMPACT:
We are investing in research, studies and thought leadership to quantify and share the importance of the work we are doing (please reach out for more information).
Completed a white paper outlining the anticipated impact of our Jefferson County site. Please reach out to request a copy.
Modeled the macroeconomic and food security impacts benefits of our product on US egg supply and prices (see graph below)
Launched a video series discussing the root causes of and solutions to the global egg supply crisis which can be found here .
3. Commercial Engagement: Market Response Continues to Grow
100+ companies now trialing Bioalbumen® in baking, snacks, and RTE foods
2,500+ samples served across NRA, R&DA, and FFT Chicago
Strong functional feedback confirms Bioalbumen®’s performance across formats
“Transitioning from plant-based proteins to working with Bioalbumen® was like going from driving a Fiat to a Ferrari.” — Chef & Alternative Protein Expert
4. Team Update: An Important Week in Helsinki
In June, we hosted a company-wide strategy week in Helsinki with participation from our global team and investors. The agenda focused on near-term execution and covered a wide-array of topics from IP strategy to manufacturing and quality, from marketing and commercial activity to finance.
We also celebrated with a Bioalbumen®-powered midsummer dinner and team-building at our Helsinki home.
“Honestly, what an amazing team we have. I’m blown away by the strength of our organization, the quality of people and their commitment to cause.” - Onego Employee
5. Looking Ahead to Series B
We’re currently structuring the details of the upcoming Series B. In addition to the support and interest we continue to receive from the US government, we also have and are actively receiving funding from our public partners at the European Investment Committee. The public-sector momentum not only validates the urgency and relevance of our work, but also signals a growing recognition that solutions like ours are essential to national and global resilience.
The Series B funds will be used for:
Scaling up contract manufacturing volumes at positive unit economics
R&D: continuous improvement on bioprocess and strain development
Factory engineering: process optimization and efficiency metrics
Customer development: sales team expansion and continuous application development
Supply chain refinement: order-to-cash process, quality and compliance
Market expansion: regulatory approval strategy & pathways for new markets
IP: new patents and other strengthening IP
Building blended finance cap stack: matching grants, concessional loans, project finance
If you’d like to request a copy of the pitch deck, please get in touch below:
6. Upcoming Events: Meet Us in H2
We’re actively engaging with customers, partners, and investors at the below events in the second half of 2025. If you or your teams are attending any of these, let’s connect.
IBIE – Las Vegas, September
Future Food-Tech – London, September
World Expo – Osaka (with Finland’s Ministry of Agriculture and Forests), September
SupplySide West – Las Vegas, October
SLUSH – Helsinki, November
If you’re tracking our journey or ready to get more involved, we’re always open to a conversation.
Let’s Connect
Together, we can address some of the most pressing challenges in our food system. Reach out and let’s talk!
